Business

SCHOTT Pharma AG & Co. KGaA: Outlook for fiscal year 2026 and update of mid-term guidance

SCHOTT Pharma AG & Co. KGaA: Outlook for fiscal year 2026 and update of mid-term

Schott Pharma Ag & Co. KgaaDecember 4, 20255
SCHOTT Pharma AG & Co. KGaA: Outlook for fiscal year 2026 and update of mid-term guidance

About this update from Schott Pharma Ag & Co. Kgaa

EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Change in Forecast SCHOTT Pharma AG & Co. KGaA: Outlook for fiscal year 2026 and update of mid-term guidance 04-Dec-2025 / 18:53 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group . The issuer is solely responsible for the content of this announcement. SCHOTT Pharma: Outlook for fiscal year 2026 and update of mid-term guidance Today, SCHOTT Pharma issues its financial guidance for fiscal year 2026: The company expects revenue growth at constant currencies in the range of 2-5% and an EBITDA margin of around 27%. This projection deviates from current market expectations (source: Vara consensus as of December 3, 2025) of 8.2% growth at constant currencies and an EBITDA margin of 28.8%. Further, SCHOTT Pharma updates its mid-term outlook for 2027 to 2029 to a revenue CAGR of 6-8% and expects the EBITDA margin to improve over the coming years towards 30%. Preliminary results for fiscal year 2025 are in line with market expectations and will be published in a press release later today. The full set of results for fiscal 2025 will be published on December 11, 2025, at 07:00 a.m. CET. End of Inside Information 04-Dec-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News Language: English Company: SCHOTT Pharma AG & Co. KGaA Hattenbergstraße 10 55122 Mainz Germany ISIN: DE000A3ENQ51 WKN: A3ENQ5 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 2240736   End of Announcement EQS News Service 2240736  04-Dec-2025 CET/CEST

View stock analysis, news, and events for Schott Pharma Ag & Co. Kgaa

More from Schott Pharma Ag & Co. Kgaa

All Schott Pharma Ag & Co. Kgaa news →